Vyripharm Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $300M

  • Investors
  • 1

Vyripharm General Information

Description

Developer of a biopharmaceutical innovator intended to focus on integrating traditional and alternative medicine. The company develops drugs to target cancer, drug addiction, and metabolic diseases and aims in improving clinical management through diagnosis and treatment with botanicals, synthetic pharmaceuticals, and drug delivery systems, enabling patients to cure infectious diseases, neurological disorders, and cancer.

Contact Information

Formerly Known As
Vyripharm Enterprises
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2405 Almeda Road
  • Suite 300591
  • Houston, TX 77054
  • United States
+1 (713)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 2405 Almeda Road
  • Suite 300591
  • Houston, TX 77054
  • United States
+1 (713)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vyripharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 28-Oct-2021 $300M Completed Generating Revenue
2. Angel (individual) 02-Aug-2016 Cancelled Generating Revenue
1. Accelerator/Incubator 16-May-2016 Completed Generating Revenue
To view Vyripharm’s complete valuation and funding history, request access »

Vyripharm Patents

Vyripharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220305145-A1 Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm Inactive 26-Mar-2021
WO-2022204416-A1 Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm Inactive 26-Mar-2021
US-20220370650-A1 Formulations and kits for the diagnostic evaluation of infectious diseases and methods thereof Inactive 26-Mar-2021
WO-2022204414-A1 Formulations and kits for the diagnostic evaluation of infectious diseases and methods thereof Inactive 26-Mar-2021
US-20220305148-A1 Natural cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases Inactive 26-Mar-2021 A61K51/0497
To view Vyripharm’s complete patent history, request access »

Vyripharm Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Texas Medical Center Venture Capital Minority
To view Vyripharm’s complete investors history, request access »

Vyripharm Investments (1)

Vyripharm’s most recent deal was a Joint Venture with Pharmaceutical cannabinoids research JV (Alamo CBD/Vyripharm Enterprises). The deal was made on 03-Jan-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pharmaceutical cannabinoids research JV (Alamo CBD/Vyripharm Enterprises) 03-Jan-2017 Joint Venture Other Pharmaceuticals and Biotechnology
To view Vyripharm’s complete investments history, request access »

Vyripharm FAQs

  • When was Vyripharm founded?

    Vyripharm was founded in 2014.

  • Where is Vyripharm headquartered?

    Vyripharm is headquartered in Houston, TX.

  • What industry is Vyripharm in?

    Vyripharm’s primary industry is Drug Discovery.

  • Is Vyripharm a private or public company?

    Vyripharm is a Private company.

  • What is Vyripharm’s current revenue?

    The current revenue for Vyripharm is .

  • How much funding has Vyripharm raised over time?

    Vyripharm has raised $300M.

  • Who are Vyripharm’s investors?

    Texas Medical Center has invested in Vyripharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process